Antimalarial drugs could support existing cancer treatments
Chloroquine and hydroxychloroquine could make cancer treatments more effective...
List view / Grid view
Chloroquine and hydroxychloroquine could make cancer treatments more effective...
Glatiramer acetate, a drug used to treat multiple sclerosis, has been found to have an effect on drug-resistant bacteria...
The Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), Mike Thompson responds to the UK’s Budget announcement...
The EC has granted approval to broaden the existing marketing authorisation for Zytiga to include early stage metastatic prostate cancer...
A cheap and widely used drug, used to treat conditions such as heartburn, gastritis and ulcers, could work against the bacteria that cause TB...
The EMA has granted a Marketing Authorization for Zubsolv, a novel rapidly-disintegrating treatment option for opioid dependence...
Drugs designed to halt cancer growth may offer a new way to control high blood pressure...
Boehringer Ingelheim has announced the launch of a new platform offering free and open access to selected pre-clinical molecules for a non-clinical investigation to scientists worldwide...
The EMA will relocate to Amsterdam in the Netherlands. The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest...
Hemlibra has been approved to prevent the frequency of bleeding episodes in patients who have developed FVIII inhibitors...
Cell-weighing technique may predict which therapies a patient is most sensitive or resistant to...
Chloroquine found to reduced the amount of Zika virus in maternal blood and neural progenitor cells in the foetal brain
Wayne Pines, President of Healthcare at APCO Worldwide in Washington DC and a former Associate Commissioner of the FDA believes Milan is a logical choice for the relocation of the European Medicines Agency...
A Norwegian study shows that NTZ contains a substance that can kill prostate and colon cancer...
The FDA has approved Fasenra for the add-on maintenance treatment of patients with severe asthma aged 12 years and older...